Journal
BREAST
Volume 38, Issue -, Pages 132-135Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2018.01.001
Keywords
Male breast cancer; ER; HER2; AR; Molecular profile; Genetics; Epigenetics; Prognosis
Categories
Ask authors/readers for more resources
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare. Using hierarchical clustering in FBC, ER alpha clustered with PR, whereas in MBC, ER alpha associated with ER beta and AR. Based on limited data it appears that Oncotype DX is effective in determining recurrence risk in selected MBC. In future, tailored therapies based on genomics will probably yield the most promising approach for both MBC and FBC. (c) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available